Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Kidney Neoplasms. Found 94 abstracts

no pagination
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020 Apr;203(4):690-8.
Minervini A, Campi R, Lane BR, De Cobelli O, Sanguedolce F, Hatzichristodoulou G, Antonelli A, Noyes S, Mari A, Rodriguez-Faba O, Keeley FX, Langenhuijsen J, Musi G, Klatte T, Roscigno M, Akdogan B, Furlan M, Karakoyunlu N, Marszalek M, Capitanio U, Volpe A, Brookman-May S, Gschwend JE, Smaldone MC, Uzzo RG, Carini M, Kutikov A. Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. J Urol. 2020 Mar;203(3):496-504.
Ahmad AE, Kutikov A, Finelli A. Needle Tract Seeding Following Renal Tumor Biopsy: Scarcely a Concern or a Concern to Scare?. Eur Urol. 2019 May;75(5):868-70.   PMCID: Editorial
Chien CR, Geynisman DM, Kim B, Xu Y, Shih YT. Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. PharmacoEconomics. 2019 Mar;37(3):301-31.   PMCID: PMC6886358
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DY, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Journal for immunotherapy of cancer. 2018 Oct 22;6(1):109.   PMCID: PMC6196426
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86.
Haifler M, Pence I, Sun Y, Kutikov A, Uzzo RG, Mahadevan-Jansen A, Patil CA. Discrimination of malignant and normal kidney tissue with short wave infrared dispersive Raman spectroscopy. Journal of biophotonics. 2018 Jun;11(6):e201700188.
Joshi SS, Handorf EA, Zibelman M, Plimack ER, Uzzo RG, Kutikov A, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. Eur Urol. 2018 Sep;74(3):387-93.
Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthelemy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2018 Apr 05;378(14):1277-90.   PMCID: PMC5972549
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017 Feb 20;35(6):668-80.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Haifler M, Kutikov A. Current Role of Renal Biopsy in Urologic Practice. The Urologic clinics of North America. 2017 May;44(2):203-11.
Ito T, Derweesh IH, Ginzburg S, Abbosh PH, Raheem OA, Mirheydar H, Hamilton Z, Chen DY, Smaldone MC, Greenberg RE, Viterbo R, Kutikov A, Uzzo RG. Perioperative Outcomes Following Partial Nephrectomy Performed on Patients Remaining on Antiplatelet Therapy. J Urol. 2017 Jan;197(1):31-6.
Joshi SS, Uzzo RG. Renal Tumor Anatomic Complexity: Clinical Implications for Urologists. The Urologic clinics of North America. 2017 May;44(2):179-87.
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Kidney Neoplasms

Kidney Neoplasms Renal Cell Carcinoma Aged Middle Aged Male Female drug therapy pathology therapeutic use methods administration & dosage Adult Antineoplastic Agents surgery Disease-Free Survival mortality 80 and over Aged adverse effects therapy Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Time Factors Retrospective Studies Sunitinib carcinoma Survival Rate diagnosis Nephrectomy epidemiology Kidney cancer Risk Factors antagonists & inhibitors Prospective Studies renal cell statistics & numerical data secondary Indoles Follow-Up Studies Renal mass Pyrroles Sulfonamides Renal cell carcinoma Biopsy Neoplasm Staging Tumor Biomarkers Kidney Pyrimidines Oral Administration Risk Assessment Adjuvant Chemotherapy United Kingdom Pyrazines Aspirin Diagnosis diagnostic imaging Infrared Rays Neoplasm Seeding metabolism Clear Cell Adenocarcinoma classification Immune checkpoint inhibitor Angiogenesis Inhibitors Prior Authorization Intention to Treat Analysis Socioeconomic Factors Vascular Endothelial Growth Factor A Age Factors Survival Analysis Targeted therapy Nephroureterectomy blood Differential Diagnosis Amino acids Phenylurea Compounds Glomerular Filtration Rate Transitional Cell Carcinoma Patient Readmission High-Volume Hospitals Local Neoplasm Recurrence Nivolumab Cost of Illness Intravenous Administration Health Services Accessibility Pharmaceutical Services Insurance Metastatic renal cell carcinoma Raman spectroscopy urinary tract Pazopanib Young Adult Registries Prostatic Neoplasms Biological Models Urothelium Randomized Controlled Trials as Topic etiology genetics acute kidney injury cytology drug effects Perioperative Period adverse Cancer survival Ureteral Neoplasms local Phase III Clinical Trials as Topic Double-Blind Method Nephrometry score hemorrhage effects Prognosis Blood Transfusion Case-Control Studies United States Urological Diagnostic Techniques Tryptophan Margins of Excision Sorafenib nephrectomy Postoperative Complications urothelium Surgical Blood Loss economics Ipilimumab Quality of Life enzymology Histidine Neoplasm Proteins Tertiary Care Centers Immunotherapy Tumor complexity Monoclonal Antibodies-Humanized pharmacology Antiangiogenic Raman Spectrum Analysis Single-Blind Method Operative Time standards clopidogrel Immunological Antineoplastic Agents Laparoscopy Urology Deductibles and Coinsurance Programmed Cell Death 1 Receptor Clinical Decision-Making tissue diagnosis Axitinib Medical Assistance Medical Oncology Multicenter Studies as Topic Neoplasm Grading
Last updated on Saturday, July 04, 2020